139 related articles for article (PubMed ID: 37658484)
21. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
22. Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas.
de Pádua Covas Lage LA; Culler HF; Barreto GC; Reichert CO; Levy D; de Oliveira Costa R; Rocha V; Pereira J
Clin Epigenetics; 2022 Dec; 14(1):180. PubMed ID: 36536430
[TBL] [Abstract][Full Text] [Related]
23. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
[TBL] [Abstract][Full Text] [Related]
24. Detection of mutation profiles and tumor mutation burden of cerebrospinal fluid circulating DNA by a cancer genomic panel sequencing in glioma patients.
Guo W; Jin L; Liang J; Lin G; Zheng J; Zhou D; Zhan S; Sun H; Jiang X
Clin Chim Acta; 2022 Sep; 534():81-92. PubMed ID: 35810802
[TBL] [Abstract][Full Text] [Related]
25. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
[TBL] [Abstract][Full Text] [Related]
26. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
27. Tumor mutational burden is associated with poor outcomes in diffuse glioma.
Wang L; Ge J; Lan Y; Shi Y; Luo Y; Tan Y; Liang M; Deng S; Zhang X; Wang W; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Mar; 20(1):213. PubMed ID: 32164609
[TBL] [Abstract][Full Text] [Related]
28. Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.
Pighi C; Cheong TC; Compagno M; Patrucco E; Arigoni M; Olivero M; Wang Q; López C; Bernhart SH; Grande BM; Poggio T; Langellotto F; Bonello L; Dall'Olio R; Martínez-Martín S; Molinaro L; Francia di Celle P; Whitfield JR; Soucek L; Voena C; Calogero RA; Morin RD; Staudt LM; Siebert R; Zamò A; Chiarle R
Blood Adv; 2021 Dec; 5(23):5239-5257. PubMed ID: 34625792
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
[No Abstract] [Full Text] [Related]
30. Circulating tumor DNA in NK/T and peripheral T cell lymphoma.
Huo YJ; Zhao WL
Semin Hematol; 2023 Jul; 60(3):173-177. PubMed ID: 37563073
[TBL] [Abstract][Full Text] [Related]
31. Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified.
Laginestra MA; Cascione L; Motta G; Fuligni F; Agostinelli C; Rossi M; Sapienza MR; Righi S; Broccoli A; Indio V; Melle F; Tabanelli V; Calleri A; Novero D; Facchetti F; Inghirami G; Sabattini E; Bertoni F; Pileri SA
Mod Pathol; 2020 Feb; 33(2):179-187. PubMed ID: 31028364
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumor DNA in Hodgkin lymphoma.
Maco M; Kupcova K; Herman V; Ondeckova I; Kozak T; Mocikova H; Havranek O;
Ann Hematol; 2022 Nov; 101(11):2393-2403. PubMed ID: 36074181
[TBL] [Abstract][Full Text] [Related]
33. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
34. Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer.
Dobilas A; Chen Y; Brueffer C; Leandersson P; Saal LH; Borgfeldt C
Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):763-770. PubMed ID: 38035709
[TBL] [Abstract][Full Text] [Related]
35. Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.
Aoude LG; Brosda S; Ng J; Lonie JM; Belle CJ; Patel K; Koufariotis LT; Wood S; Atkinson V; Smithers BM; Pearson JV; Waddell N; Barbour AP; Bonazzi VF
J Mol Diagn; 2023 Oct; 25(10):771-781. PubMed ID: 37544359
[TBL] [Abstract][Full Text] [Related]
36. Ataxia telangiectasia gene mutations in leukaemia and lymphoma.
Boultwood J
J Clin Pathol; 2001 Jul; 54(7):512-6. PubMed ID: 11429421
[TBL] [Abstract][Full Text] [Related]
37. Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
Chow YP; Zainul Abidin N; Kow KS; Tho LM; Wong CL
PLoS One; 2022; 17(10):e0276161. PubMed ID: 36256645
[TBL] [Abstract][Full Text] [Related]
38. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
40. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
